Engineered opsonin protein captures circulating tumor cells in the bloodstream with high efficiency
- Source:
- Wyss Institute for Biologically Inspired Engineering at Harvard
- Summary:
- Scientists have adapted an engineered human blood opsonin protein known as FcMBL, which was originally developed as a broad-spectrum pathogen capture agent, to target circulating tumor cells — the notoriously rare and difficult-to-locate agents of metastasis. Using magnetic beads coated with FcMBL, they were able to capture >90 percent of seven different types of cancer cells, demonstrating that the approach could be valuable in cancer diagnostics and monitoring.
Follow the Neptune Prime channel on WhatsApp:
Do you have breaking news, interview request, opinion, suggestion, or want your event covered? Email us at neptuneprime2233@gmail.com
